register

News & Trends - Pharmaceuticals

Leukaemia Foundation awards $120k to enhance research into immunoglobulin therapy

Health Industry Hub | November 28, 2019 |

The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) have collaborated to award Monash University PhD student Dr Khai Li Chai a three-year, $120,000 scholarship.

The funding will support Dr Chai’s research into hypogammaglobulinaemia in people living with a range of blood cancers: chronic lymphocytic leukaemia (CLL), non- Hodgkin’s lymphoma (NHL) and multiple myeloma, and individuals who have undergone stem cell transplants.

Hypogammaglobulinaemia is a condition where the body does not produce enough antibodies and can be associated with serious and recurrent infections. It is a significant cause of mortality and morbidity in affected patients.

Dr Chai’s work will evaluate the efficacy, standard of practice and clinical outcomes of immunoglobulin therapy, which is frequently administered to patients with hypogammaglobulinaemia. Her work will investigate how detailed patient immune profiles can be used to guide and monitor optimal dosing and duration of immunoglobulin therapy to develop a more clearly defined and effective standard of care.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

Leukaemia Foundation CEO Bill Petch said “Over the past 17 years the National Research Program has supported 506 researchers and co-investigators to undertake 278 research projects through PhD scholarships, clinical and post-doctoral fellowships and research grants,”

“The investment into research has contributed to the development of many new techniques and therapies which are now either undergoing clinical trials or are being used in clinics as part of everyday therapy. This includes treatments like Venetoclax, bortezomib, CAR T-cell therapy and liquid biopsies for blood cancers – a world first.”

The Leukaemia Foundation receives no ongoing government funding, and the National Research Program relies on the continued support of generous donation.

You may also like Recognising cutting-edge Australian research


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.